Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MIS 416

Drug Profile

MIS 416

Alternative Names: MIS-416

Latest Information Update: 28 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Virionyx
  • Developer Amplia Therapeutics Limited; Innate Immunotherapeutics
  • Class Adjuvants; Anti-infectives; Antineoplastics; Neuroprotectants
  • Mechanism of Action Immunomodulators; Immunostimulants; NOD2 protein agonists; NOD2 protein modulators; Toll-like receptor 9 agonists; Toll-like receptor 9 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Cancer
  • No development reported Infections
  • Discontinued Multiple sclerosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Jun 2018 Adverse events and immunogenicity data from a phase I trial in Solid tumours presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 23 Mar 2018 Preclinical development for cancer is ongoing in New Zealand
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top